Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.45 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778686 | 0.77 | DPP4 (0.48) | MAPTKDM4EDPP4DPP8DPP9 | |
| SCHEMBL4085247 | 0.77 | CNR1 (0.57) | MAPTKDM4EDPP4DPP8DPP9 | |
| SCHEMBL522136 | 0.76 | KMT2A (0.59) | MAPK1MAPTKDM4ETSHRPOLB | |
| SCHEMBL11225504 | 0.76 | CYP4F2 (0.67) | MAPK1MAPTKDM4ETSHRBAZ2B | |
| SCHEMBL4080087 | 0.74 | CNR1 (0.59) | MAPTKDM4EDPP4DPP8DPP9 | |
| SCHEMBL235046 | 0.74 | TSHR (0.60) | MAPK1MAPTKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL1866115 | 0.74 | MAPT (0.50) | MAPK1MAPTKDM4ETSHRNPC1 | |
| SCHEMBL6698273 | 0.73 | MAPT (0.53) | MAPTKDM4EDPP4DPP8DPP9 | |
| SCHEMBL14886652 | 0.73 | MAPK1 (0.70) | MAPK1MAPTTSHRNPC1RAB9A | |
| SCHEMBL5922344 | 0.73 | MAPT (0.50) | MAPK1MAPTKDM4ETSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6734185-B2 | Pyrrolo[3,4-d]pyrimidines as corticotropin releasing factor (CRF) antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-05-11 | — | — | US | disclosed |
| US-20030220333-A1 | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists | BAKTHAVATCHALAM RAJAGOPAL (US) | 2003-11-27 | — | — | US | disclosed |
| US-6630476-B2 | For therapy of anxiety, depression, and other psychiatric, neurological disorders, immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-07 | — | — | US | disclosed |
| US-20020022632-A1 | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022632-A1 | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists | CRH, CRHR1, CRHR2 | MAPK1 757/4885MAPT 3449/4885KDM4E 4590/4885 |
| US-20030220333-A1 | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists | CRH, CRHR1, CRHR2 | MAPK1 852/4885MAPT 3573/4885KDM4E 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.